125 related articles for article (PubMed ID: 25984040)
1. Successful cinacalcet treatment of refractory secondary hyperparathyroidism due to multiple lung parathyroid adenomas.
Sugi O; Kimata N; Miwa N; Otsubo S; Nitta K; Akiba T
NDT Plus; 2010 Feb; 3(1):60-3. PubMed ID: 25984040
[TBL] [Abstract][Full Text] [Related]
2. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
3. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
[TBL] [Abstract][Full Text] [Related]
4. Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism.
Lu KC; Ma WY; Yu JC; Wu CC; Chu P
Clin Endocrinol (Oxf); 2012 May; 76(5):634-42. PubMed ID: 22007930
[TBL] [Abstract][Full Text] [Related]
5. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
Yuan F; Chen X; Wang C; Zhou A; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
[TBL] [Abstract][Full Text] [Related]
6. [Total parathyroidectomy in treatment of Sagliker syndrome in 10 cases of hemodialysing patients with secondary hyperparathyroidism].
Zhang L; Yao L; Hua Z; Bian WJ; Li WG
Zhonghua Nei Ke Za Zhi; 2011 Jul; 50(7):562-7. PubMed ID: 22041265
[TBL] [Abstract][Full Text] [Related]
7. Association between increased serum osteoprotegerin levels and improvement in bone mineral density after parathyroidectomy in hemodialysis patients.
Zheng CM; Chu P; Wu CC; Ma WY; Hung KC; Hsu YH; Lin YF; Diang LK; Lu KC
Tohoku J Exp Med; 2012 Jan; 226(1):19-27. PubMed ID: 22156488
[TBL] [Abstract][Full Text] [Related]
8. [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH].
Zwiech R; Dryja P; Łacina D; Nykiel P; Sek-Szczepanowska K; Bratkowska K; Pietrzak B; Chrul S
Wiad Lek; 2011; 64(4):267-73. PubMed ID: 22533150
[TBL] [Abstract][Full Text] [Related]
9. Parathyroidectomy leads to decreased blood lead levels in patients with refractory secondary hyperparathyroidism.
Chu P; Wu CC; Chen CC; Lu KC
Bone; 2012 May; 50(5):1032-8. PubMed ID: 22373954
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
[TBL] [Abstract][Full Text] [Related]
11. Survival after parathyroidectomy in chronic hemodialysis patients with severe secondary hyperparathyroidism.
Moldovan D; Racasan S; Kacso IM; Rusu C; Potra A; Bondor C; Patiu IM; Gherman-Căprioară M
Int Urol Nephrol; 2015 Nov; 47(11):1871-7. PubMed ID: 26377492
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients.
Aladrén Regidor MJ
Clin Nephrol; 2009 Feb; 71(2):207-13. PubMed ID: 19203518
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of parathyroidectomy versus cinacalcet in the clinical management of secondary hyperparathyroidism.
Kim WW; Rhee Y; Kim BS; Kim K; Lee CR; Kang SW; Lee J; Jeong JJ; Nam KH; Chung WY
Endocr J; 2019 Oct; 66(10):881-889. PubMed ID: 31189770
[TBL] [Abstract][Full Text] [Related]
14. Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism.
Yuan F; Chen X; Wang C; Li Z; Liu H
Blood Purif; 2018; 45(1-3):73-78. PubMed ID: 29216631
[TBL] [Abstract][Full Text] [Related]
15. Parathyroidectomy in patients with chronic kidney disease: Impacts of different techniques on the biochemical and clinical evolution of secondary hyperparathyroidism.
Albuquerque RFC; Carbonara CEM; Martin RCT; Dos Reis LM; do Nascimento CP; Arap SS; Moysés RMA; Jorgetti V; Montenegro FLM; de Oliveira RB
Surgery; 2018 Feb; 163(2):381-387. PubMed ID: 29146232
[TBL] [Abstract][Full Text] [Related]
16. [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
Mpio I; Boumendjel N; Karaaslan H; Arkouche W; Lenz A; Cardozo C; Cardozo J; Pastural-Thaunat M; Fouque D; Silou J; Attaf D; Laville M
Nephrol Ther; 2011 Jul; 7(4):229-36. PubMed ID: 21353659
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease.
Arenas Morales AJ; DeFreitas MJ; Katsoufis CP; Seeherunvong W; Chandar J; Zilleruelo G; Freundlich M; Abitbol CL
Pediatr Nephrol; 2019 Jan; 34(1):129-135. PubMed ID: 30203374
[TBL] [Abstract][Full Text] [Related]
18. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.
Lien YH; Silva AL; Whittman D
Nephrol Dial Transplant; 2005 Jun; 20(6):1232-7. PubMed ID: 15840675
[TBL] [Abstract][Full Text] [Related]
19. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
